# OnCo record naxitamab-201 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/naxitamab-201/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "naxitamab-201", "NCT03363373" ;
  schema:name "Naxitamab Study 201"@en ;
  schema:description "Study 201 was the single-arm phase 2 of 74 patients behind naxitamab's approval for relapsed or refractory high-risk neuroblastoma in bone or bone marrow: given with GM-CSF as an outpatient, the antibody produced responses in half of patients. Without a randomised comparison against dinutuximab, equal efficacy is unproven."@en ;
  schema:url <https://onco.cc/trials/naxitamab-201/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03363373> ;
  onco:status "positive" ;
  onco:phase "2" ;
  schema:startDate "2018-04-03" ;
  onco:cancers <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/neuroblastoma-high-risk/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/naxitamab/> ;
  onco:companies <https://onco.cc/companies/y-mabs/> ;
  onco:people <https://onco.cc/people/nai-kong-cheung/> .